Goldman Sachs Maintains Neutral on Maravai LifeSciences, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes has maintained a Neutral rating on Maravai LifeSciences (NASDAQ:MRVI) and lowered the price target from $12 to $8.
August 08, 2023 | 2:38 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Goldman Sachs has maintained a Neutral rating on Maravai LifeSciences and lowered the price target from $12 to $8.
The lowering of the price target by Goldman Sachs from $12 to $8 indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on Maravai LifeSciences' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100